This promotional website is
intended for UK healthcare professionals only
This promotional website is intended for UK healthcare professionals only
- Adverse event reporting
- UK Prescribing Information
- Contact us
ENHERTU (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens1
ENHERTU as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy1
Enhertu has a Conditional Marketing Authorisation
PUSH THE PARADIGM: For second-line HER2+ metastatic breast cancer patients
ENHERTU is a HER2-directed antibody-drug conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting.1
DESTINY-Breast03 study: a head-to-head study of ENHERTU vs T-DM12
DESTINY-BREAST03 ➤The DESTINY-Breast02 study: evaluated ENHERTU vs TPC in patients previously treated with T-DM13
DESTINY-BREAST02 ➤ENHERTU is reimbursed in England, Wales, Northern Ireland and Scotland in second-line HER2+ mBC.4,5
The NICE recommendation states that trastuzumab deruxtecan is recommended with managed access as an option for treating HER2-positive unresectable or metastatic breast cancer after one or more anti-HER2 treatments in adults. It is only recommended if the conditions in the managed access agreement for trastuzumab deruxtecan are followed.4
The SMC recommendation states that trastuzumab deruxtecan is accepted for restricted use within NHS Scotland as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. This advice applies only in the context of an approved NHS Scotland PAS arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.5
How does ENHERTU work?
ENHERTU is a specifically engineered HER2-directed ADC1,5,6
Ensures delivery of the toxic payload to tumour cells expressing HER2.6,7
Tumour-selective cleavable linker6,7
Linker-payload is stable in plasma and cleaved by proteases highly expressed in cancer cells for enhanced, tumour-specific delivery of toxic payload
High-potency topoisomerase I inhibitor6,7
Highly potent payload is an exatecan derivative, known as DXd, and is more potent than SN-38, the active metabolite of irinotecan1
High antibody-drug ratio and membrane-permeable toxin6–9
Enables reliable and consistent delivery of toxic payload (8:1 drug-to-antibody ratio) to the tumour and the neighbouring cells, with and without HER2 expression (bystander anti-tumour effect).
The proposed mechanism of action is based on pre-clinical data and clinical outcomes cannot be inferred.
The proposed mechanism of action is based on pre-clinical data and clinical outcomes cannot be inferred.
Tumour-selective cleavable linker6,7
Linker-payload is stable in plasma and cleaved by proteases highly expressed in cancer cells for enhanced, tumour-specific delivery of toxic payload
High-potency topoisomerase I inhibitor6,7
Highly potent payload is an exatecan derivative, known as DXd, and is more potent than SN-38, the active metabolite of irinotecan1
High antibody-drug ratio and membrane-permeable toxin6–9
Enables reliable and consistent delivery of toxic payload (8:1 drug-to-antibody ratio) to the tumour and the neighbouring cells, with and without HER2 expression (bystander anti-tumour effect).
Abbreviations
ADC, antibody-drug conjugate; DXd, deruxtecan derivative; HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer; MOA, mechanism of action; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme; SMC, Scottish Medicines Consortium; T-DM1, trastuzumab emtansine; TPC, treatment of physician’s choice.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App store. Adverse events should also be reported to Daiichi Sankyo UK Pharmacovigilance on 0800 028 5122 or by email to pharmacovigilance@daiichi-sankyo.co.uk. As ENHERTU is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.
References
- ENHERTU (trastuzumab deruxtecan). Summary of Product Characteristics.
- Hurvitz SA, et al. Lancet 2023;401:105–17.
- Krop I, et al. Presented at 2022 San Antonio Breast Cancer Symposium (SABCS); 6–10 December 2022; San Antonio, TX. Abstract GS2-01.
- National Institute for Health and Care Excellence (NICE) (2023). Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments. Available at: https://www.nice.org.uk/guidance/ta862/resources/trastuzumab-deruxtecan-for-treating-her2positive-unresectable-or-metastatic-breast-cancer-after-1-or-more-antiher2-treatments-pdf-82613609326789. Last accessed: March 2025.
- Scottish Medicines Consortium. Trastuzumab deruxtecan (ENHERTU). Available at: https://www.scottishmedicines.org.uk/medicines-advice/trastuzumab-deruxtecan-enhertu-full-smc2545. Last accessed: March 2025.
- Yver A, et al. Ann Oncol 2020;31:430–4.
- Nakada T, et al. Chem Pharm Bull (Tokyo) 2019;67:173–85.
- Ogitani Y, et al. Clin Cancer Res 2016;22:5097–108.
- Ogitani Y, et al. Cancer Sci 2016;107:1039–46.
UK/ADC/09/24/0035 | March 2025
Daiichi Sankyo and AstraZeneca would love to stay in touch and share relevant information with you.
By providing your email address you will be able to receive:
Invitations to
educational events
and webinars
Updates on
our medicines
Patient support
materials and tools
All fields marked with an asterisk (*) are required
Thank you for the feedback